Polymorphisms in the regulatory region of the cyclophilin A gene influence the susceptibility for HIV-1 infection

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Rits, Maarten A N ^a   van Dort, Karel A ^a   Kootstra, Neeltje A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; BISEXUAL MALE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG ABUSE; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REGULATOR GENE; SERODIAGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; DRUG USE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PATHOLOGY; PHYSIOLOGY; REGULATORY SEQUENCE; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL; VIRUS LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOPHILIN A; DISEASE PROGRESSION; DRUG USERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REGULATORY SEQUENCES, NUCLEIC ACID; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIRAL LOAD; VIRUS REPLICATION;

EID: 58049092568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003975     Document Type: Article

References (32)

1. Braaten D, Franke EK, Luban J (1996) Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol 70: 3551-3560.
2. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP (1993) Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73: 1067-1078.
3. Franke EK, Yuan HEH, Luban J (1994) Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372: 359-362.
4. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, et al. (1996) Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87: 1285-1294.
5. Braaten D, Ansari H, Luban J (1997) The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol 71: 2107-2113.
6. Hatziioannou T, Perez-Caballero D, Cowan S, Bieniasz PD (2005) Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol 79: 176-183.
7. Sokolskaja E, Sayah DM, Luban J (2004) Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 78: 12800-12808.
8. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM (2003) Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A 100: 1298-1303.
9. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, et al. (2003) Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 9: 1138-1143.
10. Bosco DA, Eisenmesser EZ, Pochapsky S, Sundquist WI, Kern D (2002) Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci U S A 99: 5247-5252.
11. Berthoux L, Sebastian S, Sokolskaja E, Luban J (2005) Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A 102: 14849-14853.
12. Keckesova Z, Ylinen LM, Towers GJ (2006) Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 80: 4683-4690.
13. Stremlau M, Song B, Javanbakht H, Perron M, Sodroski J (2006) Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 351: 112-120.
14. Rits MA, van Dort KA, Munk C, Meijer AB, Kootstra NA (2007) Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein. Mol Ther 15: 930-937.
15. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
16. Sayah DM, Sokolskaja E, Berthoux L, Luban J (2004) Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430: 569-573.
17. Nisole S, Lynch C, Stoye JP, Yap MW (2004) A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A 101: 13324-13328.
18. De Roda Husman AM, Koot M, Cornelissen M, Brouwer M, Broersen SM, et al. (1997) Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 127: 882-890.
19. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, et al. (1997) Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277: 959-965.
20. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, et al. (1998) Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 279: 389-393.
21. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H (1998) The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 12: F85-F90.
22. An P, Bleiber G, Duggal P, Nelson G, May M, et al. (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 78: 11070-11076.
23. An P, Duggal P, Wang LH, O'Brien SJ, Donfield S, et al. (2007) Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 3: e19.
24. van Manen D, Rits MA, Beugeling C, van Dort KA, Schuitemaker H, et al. (2008) The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 4: e18.
25. An P, Wang LH, Hutcheson-Dilks H, Nelson G, Donfield S, et al. (2007) Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog 3: e88.
26. Bleiber G, May M, Martinez R, Meylan P, Ott J, et al. (2005) Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J Virol 79: 12674-12680.
27. Centers for disease control (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 36 (suppl 1): 1S-15S.
28. Centers for disease control (1993) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 (RR-17): 1-19.
29. Schinkel J, Langendam M, Coutinho RA, Krol A, Brouwer M, et al. (1999) No evidence for an effect of the CCR5 Δ32/+ and the CCR2b 64I/+ mutations on Human Immunodeficiency Virus type 1 (HIV-1) disease progression disease progression among HIV-1 infected injecting drug users. J Infect Dis 179: 825-831.
30. Palacin M, Rodriguez I, Garcia-Castro M, Ortega F, Reguero JR, et al. (2008) A search for cyclophilin-A gene (PPIA) variation and its contribution to the risk of atherosclerosis and myocardial infarction. Int J Immunogenet 35: 159-164.
31. Geskus RB (2000) On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion. Stat Med 19: 1753-1769.
32. Tersmette M, Winkel IN, Groenink M, Gruters RA, Spence P, et al. (1989) Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 171: 149-155.